Texas Center for Cancer Nanomedicine
University of Texas Health Science Center
David G. Gorenstein, Ph.D.
Mauro Ferrari, Ph.D.
Anil Sood, M.D.
Gabriel Lopez-Berestein, M.D.
Project 1: Multistage Vectors for Ovarian Cancer Therapeutics
Project Investigators: Gabriel Lopez-Berestein, M.D., Mauro Ferrari, Ph.D., Bulent Ozpolat, M.D., Ph.D., Paolo Decuzzi, Ph.D., Haifa Shen, Ph.D., Adaikkalam Vellaichamy, Ph.D., and Jennifer West, Ph.D.
The overall goal of this Project is to demonstrate the feasibility for clinical translation of biocompatible nanoparticles with favorable pharmacokinetics and tissue distribution for the highly efficient delivery of novel anti-cancer therapeutic agents.
Project 2: Nanotechnology Platforms for Targeting Ovarian Cancer Vasculature
Project Investigators: Anil Sood, M.D., Chun Li, Ph.D., Paolo Decuzzi, Ph.D., Haifa Shen, Ph.D., Jennifer West, Ph.D., and Rebekah Drezek, Ph.D.
The progressive growth of ovarian cancer and associated metastases is dependent on an adequate blood supply (angiogenesis). The overall goal of this Project is to develop anti-angiogenesis strategies using "smart" biocompatible nanoparticles.
Project 3: Nanotechnology Platforms for the Prevention and Personalized Therapy of Pancreatic Adenocarcinoma
Project Investigators: Craig Logsdon, Ph.D., David Menter, Ph.D., Michael Swank, Ph.D., Rosa Hwang, M.D., Paolo Decuzzi, Ph.D., Adaikkalam Vellaichamy, Ph.D., Rita Serda, Ph.D., and Jennifer West, Ph.D.
The goal of this Project is to develop new strategies for managing pre-neoplastic and invasive pancreatic cancer as well as developing new nanoscale technologies for biomarker development.
Project 4: Multifunctional Nanoassemblies for Ligand-Directed Imaging and Therapy of Endocrine Pancreatic Tumors
Project Investigators: Wadih Arap, M.D., Ph.D., Renata Pasqualini, Ph.D., Paolo Decuzzi, Ph.D., Biana Godin Vilentchouk, Ph.D., Steven Libutti, M.D., and Zipian Yuan, Ph.D.
The goals of this Project are to develop new diagnostic and therapeutic nanoparticle platforms for pancreatic cancer.